drugset / Trial / NCT02753894
Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this study is to examine the clinical dose range of ASP1585 based on the efficacy, safety, and feasibility of treatment in chronic kidney disease patients on hemodialysis with hyperphosphatemia.
Timeline
- Start
- 2008-01
- Primary completion
- 2008-06
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bixalomer | Small molecule | 4.5 g | Oral |
| Subject | Bixalomer | Small molecule | 6 g | Oral |
| Subject | Bixalomer | Small molecule | 7.5 g | Oral |